All In Biotech

Drug Trial Radar · NCT07067112

Suppressive Functions of Regulatory T Cells in Migraine

Last checked: Nov 20, 2026Latest source record: Oct 14, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

24

Planned (sponsor's estimate)

Start

Sep 10, 2026

Primary completion

Nov 30, 2027

Study completion Nov 30, 2027

Sponsor

Lead sponsor
University Hospital, Clermont-FerrandAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Jul 16, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Not applicable
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Basic science
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 50 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

Migraine is a frequent, disabling condition, of great social and economical impact worldwide. This condition is more frequent in women and subjects with autoimmune and/or inflammatory diseases. Cytokine and immune cell dysregulations have been evidenced in migraine. Inflammation seems to play an important role in migraine chronification; however, the inflammatory mechanisms involved in migraine pathophysiology remain unclear. Regulatory T (Treg) cells play a central role in maintaining immune homeostasis. They regulate effector T (Teff) cell proliferation and cytokine production, through several suppressive mechanisms, such as the hydrolysis of adenosine triphosphate (ATP) into adenosine (ADO), mediated by surface enzymes Cluster Differentiation 39 (CD39) and Cluster Differentiation 73 (CD73). ATP is involved in pain processes in migraine, and insufficient hydrolysis could participate in pain chronification. Recent studies suggest altered proportions of Treg cells in migraine, and decreased levels of CD39-positive (CD39+) Treg cells, suggesting Treg suppressive functions may be decreased in the disease. However, there have been no functional studies to date to confirm this hypothesis. The investigators believe Treg suppressive functions may be decreased in migraine, and that such alterations may be caused by a malfunction in the ADO pathway.

Conditions

  • Chronic Migraine

Interventions

  • Blood sampling, questionnaire and phone callBiological

    The blood sample will drawn outside of a migraine attack (no migraine within 6 hours prior to the blood test), and the questionnaire will be auto-administered

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Treg cell suppressive functionsTime frame: Day 0

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CHU Clermont-Ferrand

    Clermont-Ferrand, France · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.